Insulin receptor activation in deletion 11q chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2605-2607

  Brown, Jennifer R ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAL 101; INSULIN RECEPTOR; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE ZAP 70; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ATAXIA TELANGIECTASIA MUTATED GENE; CHROMOSOME DELETION; CHROMOSOME DELETION 11Q; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE LOSS; GENE OVEREXPRESSION; HUMAN; LEUKEMOGENESIS; LYMPHADENOPATHY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MODELS, BIOLOGICAL; PROGNOSIS; RECEPTOR, INSULIN;

EID: 79955488811     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0295     Document Type: Note

References (12)

1. Saiya-Cork K, Collins R, Parkin B, Ouillette P, Kuizon E, Kujawski L, et al. Pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res 2011;17:2679-92.
2. D€ohner H, Stilgenbauer S, Benner A, Leupolt E, Kr€ober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6. (Pubitemid 32064784)
3. D€ohner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-22. (Pubitemid 27143300)
4. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448-57. (Pubitemid 350232222)
5. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-9. (Pubitemid 35403967)
6. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011;305:59-67.
7. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846-55.
8. Edelman G, Bedell C, Shapiro GG, Pandya S, Kwak E, Scheffold C, et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010;28:3004.
9. Furman R, Byrd J, Brown JR, Coutre S, Benson D, Wagner-Johnston N, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3 kinase p110d, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;116:31.
10. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-d inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078-88.
11. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110delta selective phosphatidylinositol- 3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117: 591-4.
12. Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100: 4609-14. (Pubitemid 35429705)